OQS
ACRV icon

Occudo Quantitative Strategies’s Acrivon Therapeutics ACRV Stock Holding History

Occudo Quantitative Strategies’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,552
Closed -$72.8K – 675
2024
Q2 		$72.8K Buy
+12,552
New +$101K 0.01% 689

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Occudo Quantitative Strategies's ACRV Position: Q3 2024 in Review

Occudo Quantitative Strategies sold out of Acrivon Therapeutics (ACRV) in Q3 2024, closing a stake of 12,552 shares — an estimated $72.8K sold.

Occudo Quantitative Strategies first reported a position in ACRV in Q2 2024 and held it in 1 quarter. The position peaked at $72.8K in Q2 2024. 55 funds tracked by Wall St. Rank hold ACRV as of Q3 2024.

  • Occudo Quantitative Strategies reported no remaining Acrivon Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 12,552 Acrivon Therapeutics shares in Q3 2024, an estimated $72.8K.
  • Occudo Quantitative Strategies first reported a position in Acrivon Therapeutics in Q2 2024 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Acrivon Therapeutics position peaked at $72.8K in Q2 2024.
  • 55 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.